L-4-噻唑丙氨酸 | 119433-80-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-4-噻唑丙氨酸
• 中文别名: 3-(4-噻唑)-L-丙氨酸
• 英文名称: (2S)-2-amino-3-(thiazol-4-yl)propanoic acid
• 英文别名: 3-(4-thiazolyl)-L-alanine；L-4-thiazolylalanine；(2S)-2-azaniumyl-3-(1,3-thiazol-4-yl)propanoate
• CAS: 119433-80-6
• 化学式: C₆H₈N₂O₂S
• 分子量: 172.208
• InChiKey: WBZIGVCQRXJYQD-YFKPBYRVSA-N

物化性质

• 沸点：
  353.3±32.0 °C(Predicted)
• 密度：
  1.433

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S35
• 危险类别码：
  R36/37/38
• 海关编码：
  2942000000
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储在-15°Celsius 下

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: L-4-Thiazolylalanine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: L-4-Thiazolylalanine
CAS number: 119433-80-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H8N2O2S
Molecular weight: 172.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

L-4-噻唑丙氨酸作为一种研究用化合物。

反应信息

• 作为反应物：
  描述：

  L-4-噻唑丙氨酸 在 N-羟基丁二酰亚胺 、 1-羟基苯并三唑 、 苯甲醚 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 (4S,5S)-5-methyl-N-{(2S)-1-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide
  参考文献：
  名称：

  促甲状腺激素释放激素模拟物的所有立体异构体：水合罗替瑞林的合成和体内抗低温作用的评估。

  摘要：

  我们发现了口服活性促甲状腺激素释放激素（TRH）模拟物：（4 S，5 S）-5-甲基-N -{（2 S）-[[（2 R）-2-甲基吡咯烷酮-1-基]] -1-氧代-3-（1,3-噻唑-4-基）丙-2-基} -2-氧代-1,3-氧唑烷-4-羧酰胺1（罗替瑞林）。静脉内（iv）给药后，罗非瑞林对中枢神经系统（CNS）的作用比TRH高100倍。由于1在其分子中具有四个不对称碳，因此有16个立体异构体。我们合成并评估了1（具有（4 S），（5 S），（2 S），（2R）从N端到C端的构型，以阐明立体异构体的结构活性关系（SAR）。（4 R），（5 R），（2 R），（2 S）-异构体16没有显示出任何抗低温作用。只有（4 S），（5 S），（2 S），（2 S）异构体10在C末端具有（2 S）-2-甲基吡咯烷部分，其抗低温作用类似于1。立体异构体，在N端具有恶唑烷酮的（5 R）构型和（2 R在中间

  DOI：

  10.1002/psc.3228
• 作为产物：
  描述：

  (S)-3-(4-thiazolyl)-2-benzoylaminopropanoic acid 在 盐酸 作用下， 反应 20.0h， 以0.24 g的产率得到L-4-噻唑丙氨酸
  参考文献：
  名称：

  Enantioselective Synthesis of (S)-3- (4-Thiazolyl)-2-tert-butoxycarbonyl- aminopropionic Acid: A Chiral Building Block for Renin Inhibitor

  摘要：

  (S)-3-(4-Thiazolyl)-2-tert-butoxycarbonylaminopropionic acid (6), an important structural constituent of the renin inhibitor, has been synthesized from (Z)-3-(4-thiazolyl)-2-benzoylaminoprop-2-enoic acid (4b) by enantioselective hydrogenation using the Ru-(S)-p-tolyl-BINAP complex as the key step, and then followed by acid hydrolysis and tert-butoxycarbonylation.

  DOI：

  10.3987/com-04-10178

文献信息

• Anti-angiogenic compounds
  申请人：Bradshaw W. Curt

  公开号：US20060205670A1

  公开（公告）日：2006-09-14

  The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

  本发明提供了包括与抗体的结合位点连接的AA靶向剂-连接剂共轭物的AA靶向化合物。提供了化合物的各种用途，包括治疗与异常血管生成相关的疾病的方法。
• PAR4 AGONIST PEPTIDES
  申请人：Bristol-Myers Squibb Company

  公开号：US20130289238A1

  公开（公告）日：2013-10-31

  The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.

  本发明提供PAR4激动肽。这些肽对于开发强大的PAR4受体测定方法非常有用。
• Parallel Solution Phase Synthesis and Preliminary Biological Activity of a 5′-Substituted Cytidine Analog Library
  作者：Omar Moukha-Chafiq、Robert C. Reynolds、Jacob C. Wilson、Timothy S. Snowden

  DOI：10.1021/acscombsci.9b00072

  日期：2019.9.9

  NIH Roadmap Initiative and the Pilot Scale Library (PSL) Program. Reaction core compounds contained -NH2 (2) and -COOH (44 and 93) groups that were coupled to a diversity of reactants in a parallel, solution phase format to produce the target library. The assorted reactants included -NH2, -CHO, -SO2Cl, and -COOH functional groups, and condensation with the intermediate core materials 2 and 44 followed

  通过美国国立卫生研究院路线图计划和中试规模库（PSL）计划的资助，合成了一个由109个成员组成的5'-取代胞苷类似物库。反应核心化合物包含-NH2（2）和-COOH（44和93）基团，这些基团以平行溶液相的形式与多种反应物偶联，生成目标库。所分类的反应物包括-NH 2，-CHO，-SO 2 Cl和-COOH官能团，并且与中间核材料2和44缩合，然后进行酸性水解，以良好的产率和高纯度产生了3-91。d-苯丙氨酸甲酯的氨基末端与44和NaOH处理的游离5'-COOH的连接产生了核心库-COOH前体93。化合物93是我们独特的二肽基胞苷类似物94-114文库的重要组成部分，它通过-COOH基团与众多商业胺的酰胺偶联，然后进行酸性脱保护作用。通过MLPCN程序对完整的最终文库进行的初步筛选显示，在不同的生物学过程中命中数不多。这些命中可以被认为是命中率领先的优化和开发研究的起点。
• METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE
  申请人：Ipsen Pharma S.A.S.

  公开号：US20160206700A1

  公开（公告）日：2016-07-21

  The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.

  本发明提供了一种改善炎症、抑制促炎细胞因子和/或趋化因子表达以及治疗与炎症发作相关的各种疾病和/或病况的方法，通过给予选择性的天然hGhrelin类似物来治疗需要治疗此类病况的受试者。
• [EN] DERIVATIVES OF DOLASTATIN 10 AND USES THEREOF<br/>[FR] DÉRIVÉS DE DOLASTATINE 10 ET UTILISATIONS DE CEUX-CI
  申请人：NEWBIO THERAPEUTICS INC

  公开号：WO2016192527A1

  公开（公告）日：2016-12-08

  Derivatives of dolastatin 10 and uses thereof, the structures of which are shown as formula I, II, III and IV are provided.

  多拉司丁10衍生物及其用途，其结构如公式I、II、III和IV所示。